Cancer Trial Access Expands Under FDA Guidance

The FDA's Oncology Center of Excellence released three final guidance documents to broaden eligibility criteria for cancer clinical trial participation. The guidances cover laboratory values, performance status, and washout periods — reducing unjustified patient exclusions to accelerate enrollment, improve trial diversity, and advance access to investigational cancer therapies.
The Pharmaletter